A real‐life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis

Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations

(2021) Paolo Gisondi et al.   Dermatology and Therapy

Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison

(2021) Angelo Ruggiero et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Real-life efficacy of guselkumab in patients with early psoriatic arthritis

(2021) Ilenia Pantano et al.   RHEUMATOLOGY

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020 – a rapid update

(2020) C.H. Smith et al.   BRITISH JOURNAL OF DERMATOLOGY

Covid‐19 and Exacerbation of Psoriasis

(2020) Resat Ozaras et al.   Dermatologic Therapy

Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey

(2020) Yehong Kuang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Philip J Mease et al.   LANCET

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

(2020) Atul Deodhar et al.   LANCET

Deciphering the Association Between Psoriasis and Obesity: Current Evidence and Treatment Considerations

(2020) Kyriaki Paroutoglou et al.   Current Obesity Reports

Real‐life experience of guselkumab in patients with psoriasis

(2020) Igor Snast et al.   Dermatologic Therapy

Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience

(2020) Matteo Megna et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Real‐life effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study

(2020) F. Benhadou et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A Head‐to‐Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate‐to‐Severe Plaque Psoriasis: 24‐Week Efficacy and Safety Results from a Randomised, Double‐Blinded Trial

(2020) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study

(2020) Angelo Ruggiero et al.   Dermatologic Therapy

Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study

(2019) Ashley Budu-Aggrey et al.   PLOS MEDICINE

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

(2019) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions

(2018) Peter Foley et al.   JAMA Dermatology

Risankizumab for the treatment of moderate to severe psoriasis

(2018) Andrea Chiricozzi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.

(2017) Annalisa Tonini et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optimizing acitretin use in patients with plaque psoriasis

(2016) Andrea Chiricozzi et al.   Dermatologic Therapy

European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC

(2015) A. Nast et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

(2014) Howard Sofen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis

(2009) Antonella Di Cesare et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY